Country: Evrópusambandið
Tungumál: enska
Heimild: EMA (European Medicines Agency)
Trientine tetrahydrochloride
GMP-Orphan SA
A16AX
trientine
Other alimentary tract and metabolism products,
Hepatolenticular Degeneration
Cuprior is indicated for the treatment of Wilson's disease in adults, adolescents and children ≥ 5 years intolerant to D-penicillamine therapy.,
Revision: 6
Authorised
2017-09-05
16 B. PACKAGE LEAFLET 17 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT CUPRIOR 150 MG FILM-COATED TABLETS trientine READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Cuprior is and what it is used for 2. What you need to know before you take Cuprior 3. How to take Cuprior 4. Possible side effects 5. How to store Cuprior 6. Contents of the pack and other information 1. WHAT CUPRIOR IS AND WHAT IT IS USED FOR Cuprior is a medicine used to treat Wilson’s disease that contains the active substance trientine. Wilson’s disease is an inherited condition in which the body cannot transport copper around the body in the normal way or remove copper in the normal way as a secretion from the liver into the gut. This means that the small amounts of copper from food and drink build up to excessive levels and can lead to liver damage and problems in the nervous system. This medicine mainly works by attaching to copper in the body which then allows it to be removed in the urine instead, helping to lower copper levels. It may also attach to copper in the gut and so reduce the amount taken up into the body. Cuprior is given to adults, adolescents and children aged 5 years and over who cannot tolerate another medicine that is used to treat this disease, called penicillamine. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE CUPRIOR DO NOT TAKE CUPRIOR - if you are allergic to trientine or any of the other ingredients of this medicine (listed in section 6). WARNINGS AND PRECAUTIONS Talk to your doctor or pharmacist before t Lestu allt skjalið
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Cuprior 150 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains trientine tetrahydrochloride equivalent to 150 mg trientine. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet) Yellow, 16 mm x 8 mm oblong film-coated tablet with a score line on each side. The tablet can be divided into equal doses. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Cuprior is indicated for the treatment of Wilson’s disease in adults, adolescents and children ≥ 5 years intolerant to D-penicillamine therapy. _ _ 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment should only be initiated by specialist physicians with experience in the management of Wilson’s disease. Posology The starting dose would usually correspond to the lowest dose in the range and the dose should subsequently be adapted according to the patient’s clinical response (see section 4.4). _ _ _Adult _ The recommended dose is between 450 mg and 975 mg (3 to 6 and a half film-coated tablets) per day in 2 to 4 divided doses. _Paediatric population _ The starting dose in paediatrics is lower than for adults and depends on age and may be calculated using body weight. The dose should subsequently be adapted according to the child’s clinical response (see section 4.4). _Children and adolescents (_ ≥ _5 years_ to 18 _ years) _ The dose is usually between 225 mg and 600 mg per day (1 and a half to 4 film-coated tablets) in 2 to 4 divided doses. _Children aged < 5 years _ The safety and efficacy of trientine in children aged < 5 years have not been established. The pharmaceutical form is not suitable for administration to children < 5 years. 3 The recommended doses of Cuprior are expressed as mg of trientine base (i.e. not in mg of the trientine tetrahydrochloride salt). _Special populations _ _Elderly _ No dose adjustment is required in elderly patients. _Renal impairment _ There is limit Lestu allt skjalið